Short Interest in Aptose Biosciences Inc. (NASDAQ:APTO) Declines By 15.7%

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the recipient of a large drop in short interest in the month of November. As of November 30th, there was short interest totalling 101,800 shares, a drop of 15.7% from the November 15th total of 120,700 shares. Based on an average daily trading volume, of 451,500 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.2% of the shares of the stock are short sold.

Analysts Set New Price Targets

Several analysts recently issued reports on APTO shares. HC Wainwright reiterated a “buy” rating and set a $2.00 price target on shares of Aptose Biosciences in a research report on Tuesday, December 10th. StockNews.com initiated coverage on Aptose Biosciences in a report on Sunday. They issued a “hold” rating on the stock.

Hedge Funds Weigh In On Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC purchased a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned approximately 9.46% of Aptose Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Price Performance

Shares of APTO stock remained flat at $0.19 on Friday. 301,482 shares of the stock were exchanged, compared to its average volume of 306,369. The firm has a 50 day simple moving average of $0.31 and a 200-day simple moving average of $0.50. Aptose Biosciences has a 52-week low of $0.13 and a 52-week high of $2.68. The firm has a market capitalization of $11.61 million, a PE ratio of -0.06 and a beta of 1.06.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.